180 Life Sciences Corp.ATNF
| Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
---|
Cash | - | - | - | 2 | 8 | 7 |
---|
Prepaid expenses and other current assets | - | - | - | 2 | 3 | 2 |
---|
Total Current Assets | 470,337 | 270,884 | 624,059 | 4 | 11 | 9 |
---|
Intangible assets, net | - | - | - | 2 | 2 | 2 |
---|
In-process research and development | - | - | - | 13 | 13 | 9 |
---|
Balance at beginning | - | - | - | 37 | 37 | - |
---|
Total Assets | 117 | 118 | 13 | 56 | 63 | 20 |
---|
Accounts payable | - | - | - | 9 | 586,611 | 2 |
---|
Accrued expenses | - | - | - | 4 | 2 | 2 |
---|
Accrued expenses - related parties | - | - | - | 454,951 | 18,370 | 188,159 |
---|
Less: Principal beginning balance loans payable – current portion | - | - | - | 968,446 | 2 | 1 |
---|
Loans payable - related parties | - | - | - | 513,082 | 81,277 | - |
---|
Derivative liabilities | - | - | - | 4 | 15 | 75,381 |
---|
Total Current Liabilities | 208,131 | 546,067 | 3 | 21 | 20 | 6 |
---|
Loans payable - noncurrent portion | - | - | - | 113,763 | 48,165 | 31,189 |
---|
Deferred tax liability | - | - | - | 4 | 4 | 3 |
---|
Total Liabilities | 4 | 5 | 7 | 25 | 23 | 8 |
---|
Common stock, $0.0001 par value; 100,000,000 shares authorized; 3,746,906 and 1,701,799 shares issued and outstanding at December 31, 2022 and 2021, respectively | 420 | 410 | 446 | 2,617 | 3,404 | 375 |
---|
Additional paid-in capital | 5 | 4 | 4 | 78 | 107 | 122 |
---|
Accumulated other comprehensive income | - | - | - | 636,886 | 817,440 | -2,885,523 |
---|
Accumulated deficit | 120,659 | 1 | 1 | -48,357,638 | -68,682,286 | -107,408,545 |
---|
Total Stockholders’ Equity | 5 | 5 | 5 | 30 | 39 | 11 |
---|
Total Liabilities and Stockholders’ Equity | 117 | 118 | 13 | 56 | 63 | 20 |
---|